LNTH vs. NEOG, RIOT, CLDX, NTLA, MYGN, TEVA, BGNE, RDY, CTLT, and QGEN
Should you be buying Lantheus stock or one of its competitors? The main competitors of Lantheus include Neogen (NEOG), Riot Platforms (RIOT), Celldex Therapeutics (CLDX), Intellia Therapeutics (NTLA), Myriad Genetics (MYGN), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Dr. Reddy's Laboratories (RDY), Catalent (CTLT), and Qiagen (QGEN).
Lantheus (NASDAQ:LNTH) and Neogen (NASDAQ:NEOG) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, community ranking, dividends and analyst recommendations.
Lantheus has a net margin of 33.72% compared to Neogen's net margin of 0.17%. Lantheus' return on equity of 54.10% beat Neogen's return on equity.
Lantheus received 2 more outperform votes than Neogen when rated by MarketBeat users. Likewise, 65.48% of users gave Lantheus an outperform vote while only 57.09% of users gave Neogen an outperform vote.
99.1% of Lantheus shares are held by institutional investors. Comparatively, 96.7% of Neogen shares are held by institutional investors. 1.5% of Lantheus shares are held by company insiders. Comparatively, 0.7% of Neogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Lantheus has higher revenue and earnings than Neogen. Lantheus is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.
In the previous week, Lantheus had 7 more articles in the media than Neogen. MarketBeat recorded 14 mentions for Lantheus and 7 mentions for Neogen. Lantheus' average media sentiment score of 1.03 beat Neogen's score of 0.90 indicating that Lantheus is being referred to more favorably in the media.
Lantheus currently has a consensus price target of $120.57, indicating a potential upside of 6.97%. Neogen has a consensus price target of $22.50, indicating a potential upside of 29.83%. Given Neogen's higher probable upside, analysts plainly believe Neogen is more favorable than Lantheus.
Lantheus has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Neogen has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500.
Summary
Lantheus beats Neogen on 15 of the 18 factors compared between the two stocks.
Get Lantheus News Delivered to You Automatically
Sign up to receive the latest news and ratings for LNTH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lantheus Competitors List
Related Companies and Tools
